Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Methodological standard · §7

CEI-MS-02 — references

Normative and informative references, and related standards in the same category.

Document identifier
CEI-MS-02/7
Series
Methodological standard
Version
1.4
Published
02 Feb 2023
Last reviewed
02 Jun 2023
Next review
02 Jun 2026
Identifier
10.71829/cei.meth.2
Certainty
High
Cycle
2023 Q1
Category
Identity

§7References

§7.1Normative references

The following are normative for this standard: compliance with the standard requires compliance with them[1,2,3].

§7.2Informative references

The following are informative: they support the reasoning of the standard without being conditions of compliance[4,5].

§7.3Related standards

No other standard in this category has been published.

Numbered reference list

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
  2. United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
  4. Kang L, Weng N, Jian W. LC–MS bioanalysis of intact proteins and peptides. Biomedical Chromatography 2020;34(1):e4633. doi:10.1002/bmc.4633 · PMID 31215680
  5. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.